Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, will deliver a corporate presentation at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, will deliver a corporate presentation at the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation is scheduled for Monday, June 30, 2025 at 11:30 AM EDT.
Investors and interested parties can access both the live and archived versions of the presentation through the Events page on the company's website, where it will remain available for a minimum of 30 days.
Details
News Market Reaction – ACRS
The recorded move for ACRS in the trading session of this news was -5.77%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT.
A live and archived webcast of the presentation will be accessible on the Events page of https://www.aclaristx.com/. The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn.
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
wroberts@aclaristx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.